Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Pittsburgh
With
Elan Pharmaceuticals
This will be a non-interventional study in that the antibiotic and its dose will be chosen by the treating team not the investigators. Patients on cefepime who have ventilator-associated pneumonia or bacteremia will be invited to participate in the study. Blood samples will be taken to determine the pharmacokinetic profile of the drug. Blood cultures will be repeated in patients with bacteremia to determine clearance of infection. A mini-BAL will be repeated in patients with ventilator-associated pneumonia to determine clearance of pneumonia.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Adults of at least 18 years of age or older
2. Culture proven ventilator associated pneumonia (VAP) or bacteremia caused by a cefepime susceptible gram negative pathogen:
* Bacteremia is defined as at least one positive blood culture
* VAP is defined by at least 10,000 cfu/ml of an organism from a bronchoalveolar lavage sample
3. Cefepime therapy (1 or 2 grams intravenously \[IV\] every \[q\] 8 hours or q 12 hours) initiated as part of standard of care
You may not be if
1. Concomitant VAP or bacteremia with a cefepime resistant organism
2. Concomitant therapy with an antimicrobial agent active against gram negative bacilli other than a single dose of aminoglycoside
3. Patients requiring surgical or interventional drainage of purulent collections
4. Pregnant or lactating women
5. Dialysis patients
6. Contraindication to blood sampling
7. Cystic fibrosis
Clareo Health | Pharmacodynamic Parameters of Two Different Doses of Cefepime
